Kimberly Gentile
Directeur Technique/Scientifique/R&D chez BIOHAVEN LTD.
Fortune : 3 M $ au 31/05/2024
Postes actifs de Kimberly Gentile
Sociétés | Poste | Début | Fin |
---|---|---|---|
BIOHAVEN LTD. | Directeur Technique/Scientifique/R&D | - | - |
Portage Pharmaceutical Ltd.
Portage Pharmaceutical Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Juvenescence Ltd., Portage Pharmaceutical Ltd. is a research and developer of biotechnology pharmaceutical drugs. The company is based in Toronto, Canada. Portage Pharmaceutical was acquired by Juvenescence Ltd. from Portage Biotech, Inc. on March 04, 2021 for $193.25 million. The CEO of the Canadian company is Frank W. Marcoux. | Directeur des opérations | - | - |
Historique de carrière de Kimberly Gentile
Anciens postes connus de Kimberly Gentile
Sociétés | Poste | Début | Fin |
---|---|---|---|
BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | Directeur/Membre du Conseil | - | 03/10/2022 |
Corporate Officer/Principal | 01/02/2014 | 03/10/2022 | |
BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01/01/2000 | 01/02/2014 |
SCIREX Corp. | Corporate Officer/Principal | 01/01/1996 | 01/06/2000 |
Formation de Kimberly Gentile
Salem State University | Undergraduate Degree |
Statistiques
Internationale
Etats-Unis | 4 |
Canada | 2 |
Opérationnelle
Corporate Officer/Principal | 3 |
Director/Board Member | 1 |
Undergraduate Degree | 1 |
Sectorielle
Health Technology | 4 |
Commercial Services | 3 |
Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 2 |
---|---|
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
BIOHAVEN LTD. | Health Technology |
Entreprise privées | 3 |
---|---|
SCIREX Corp. | Commercial Services |
Biohaven Pharmaceutical Holding Co. Ltd.
Biohaven Pharmaceutical Holding Co. Ltd. Pharmaceuticals: MajorHealth Technology Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. The company was founded in September 2013 and is headquartered in New Haven, CT. | Health Technology |
Portage Pharmaceutical Ltd.
Portage Pharmaceutical Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Juvenescence Ltd., Portage Pharmaceutical Ltd. is a research and developer of biotechnology pharmaceutical drugs. The company is based in Toronto, Canada. Portage Pharmaceutical was acquired by Juvenescence Ltd. from Portage Biotech, Inc. on March 04, 2021 for $193.25 million. The CEO of the Canadian company is Frank W. Marcoux. | Commercial Services |
- Bourse
- Insiders
- Kimberly Gentile
- Expérience